IMMUNOSTIMULATING PEPTIDES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMMPOSITIONS CONTAINING THEM

Abstract: The peptides of formula I A - x - Lys - y - B I in which: A is H, a tripeptide of formula Arg-Ala-Arg or an hexapeptide of formula Glu-Lys-Arg-Arg-Ala-Arg x and y, different one from the other, are an arginine (Arg) or a glutamic acid (Glu) residue; B is OH or a tripeptide Arg-Ala-Arg with the proviso that when A is hydrogen and x is Arg, B is different from OH comprising the steps of: a) binding the Boc-protected carboxyterminal aminoacid to a suitable resin; b) reacting the other Boc-protected aminoacids with the resin-bound carboxyterminal aminoacid in the desired sequence; c) removing the protecting groups and releasing the so obtained peptides from the resin, have valuable pharmacological properties as immunostimu­ lating agents.

Description: The present invention concerns peptides having general formula I A - x - Lys - y - B I in which: A is H, a tripeptide of formula Arg-Ala-Arg or an hexapeptide of formula Glu-Lys-Arg-Arg-Ala-Arg x and y, different one from the other, are an arginine (Arg) or a glutamic acid (Glu) residue; B is OH or a tripeptide Arg-Ala-Arg with the proviso that when A is hydrogen and x is Arg, B is different from OH. The aminoacids composing the peptides of the invention may be either of the natural, L-series or of the D-series or a racemic mixture of the two said series. Preferred peptides of the invention are those wherein either A or B are Arg-Ala-Arg, x is Arg and y is Glu. Another preferred group of peptides of the invention is that having A = Glu-Lys-Arg-Arg-Ala-Arg, x is Glu and y is Arg. A further preferred group of peptides is that having both A and B = Arg-Ala-Arg whereas x and y are independently Arg or Glu. The aminoacids are preferably selected from the L-forms even though D- or DL aminoacids, especially D-Ala or D-glutamic acid, may also be considered. The invention refers also to the process for the preparation of said peptides as well as to their use as immunostimulant agents. In the following disclosure the following abbreviations are used: Ala = L-alanine Arg = L-arginine Boc = butyloxycarbonyl D-Ala = D-alanine Glu = L-glutamic acid D-Glu = D-glutamic acid Lys = L-lysine N g = substitution on the guanidinic nitrogen of Arg. The tripeptide Arg-Ala-Arg is known from the italian patent application n. 20027 A/86 of 9.04.1986: it is endowed with immunostimulating activity and it is able to enhance both the T-cells maturation and functional abilities. Also the Arg-Lys-Glu tripeptide (splenotritin) corresponding to the 32-34 fragment of splenopoietin, a polypeptide hormone extracted from the bovine spleen and originally referred to as thymopoietin III because of its high affinity with thymopoietins I and II isolated from thymus, has immunostimulating properties, involving the maturation and functionality of T-lymphocytes (italian patent application n. 20026 A/86 of 9.04.1986; Diezel W. et al.: Biomed. Biochim. Acta 45, 1349, 1986). Similarly, the peptide Arg-Lys-Asp, differing from Arg-Lys-Glu only in the C-terminal aminoacidic residue, displays a similar behaviour (EP-A-0067425) as well as Arg-Gly-Asp, disclosed in the italian patent application n. 21575 A/87 of 4.08.1987. The peptides according to the invention proved to be active as immunostimulating agents, being effective in in vitro experimental models in promoting the maturation of murine immature T-lymphocytes and in enhancing the functionality of human T-cells. The peptides are able to restore the immune function in nude athymic mice, when administered for 5 days, 2 or 6 weeks by oral or i.p. route. Like Arg-Ala-Arg and Arg-Lys-Glu, also the peptides of the present invention are stable to the in vitro simulated gastric juice. Analogously to the two peptides above mentioned, those stability in the simulated gastric juice is related to the activity after oral administration, it has been demonstrated that also the peptides of the invention are endowed with immunostimulating activity both after oral administration and after parenteral administration. This fact represents a remarkable advantage in the therapeutic use, with particular reference to the treatment of children and of other patients who do not tolerate the parenteral administration and also as a consequence of a better patient's compliance to the described therapy. According to what above described, the compounds of the invention have such features so as to make them particularly useful in the clinical practice for the therapy both of primary and secondary deficiencies. The clinical utilities of immunostimulating compounds are described for instance in Immun. Lett. Vol. 16, 363, 1987, JAMA Vol. 258, 3005, 1987 and Drug Discovery and Development, Eds. Williams M. and Malick J.B., Humana 1987, p. 227, which are herein incorporated by reference. For the intended use, the peptides of the invention may be administered either alone or in admixture with pharmaceutically acceptable carrier, in suitable pharmaceutical formulations which are a further object of the invention. Examples of said formulations, which may be prepared using well known methods and excipients, such as those described in "Remington's Pharmaceutical Sciences Handbook", Mack Pub.Co., N.Y. USA., are tablets, capsules, syrups, and the like for the oral administration whereas for the parenteral administration suitable forms are sterile solutions or suspensions in acceptable liquids, implants, etc. The preferred dosage form is a unit dose comprising from about 0.1 to about 500 mg of a peptide of formula I or the equivalent of a pharmaceutically acceptable salt thereof, such as acetate, hydrochloride, trifluoroacetate, sulfate salts. The posology will depend on several factors such as type and seriousness of the pathologic conditions to be treated, patient's weight and sex, etc. and will be easily determined by the skilled practitioner. Generally one to four administrations a day will be prescribed. The peptides I are prepared according to conventional methods, well known in peptide chemistry, such as solid state synthesis on resins. The following non limitative examples are given as a further illustration of the invention. EXAMPLE 1 : GENERAL PROCEDURE FOR THE SOLID PHASE SYNTHESIS OF PEPTIDES 1. Preparation of resins substituted with Boc-aminoacids Chloromethylated polystyrene (1% crosslinked; 200-400 mesh) is swelled in dimethylformamide (DMF) (about 8-10 ml per g of resin), then treated with the Boc-aminoacid (1 mole per g of resin), followed by potassium fluoride (2 moles per g of resin). A small amount of solvent (5-10 ml) is then distilled off under vacuum after which the mixture is heated to 80-100°C for 16-18 hours. While cooling, the resin is filtered, washed with DMF, DMF:H₂O 1:1, H₂O, ethanol, CH₂Cl₂ and methanol and then dried under vacuum. Substitution (calculated by the weight increase) = 0.4-0.6 moles per g. 2. General synthetic procedure The suitable amount of resin substituted with the C-terminal Boc-aminoacid in the desired sequence is sequentially treated at room temperature (20-25°C) with: a) CH₂Cl₂ b) 50% CF₃COOH:CH₂Cl₂ (v/v) c) 50% CF₃COOH:CH₂Cl₂ for 25′ d) CH₂Cl₂ (3 times) e) isopropanol f) 10% triethylamine:CH₂Cl₂ (v/v) (twice) g) CH₂Cl₂ h) methanol (twice) i) CH₂Cl₂ (twice) The contact time for each treatment is 3-5 minutes except treatment c). About 10-15 ml of solvent or of solvent reagent mixture are used per g of resin in each step. j) The resin is stirred with a solution of the suitably protected, last but one Boc-aminoacid of the desired sequence (3 equivalents) in CH₂Cl₂, dicyclohexylcarbodiimide (3 equivalents) is then added thereto in CH₂Cl₂. The reaction time is at least 2-4 hours and it may last overnight (16-18 hours). The resin to which the peptide is bound is filtered and washed with CH₂Cl₂, methanol and CH₂Cl₂ and the synthesis completion is checked by the ninhydrine reaction. If the synthesis is incomplete, the same aminoacid is coupled again using half amounts of the reagents. The cycle is repeated for each aminoacid of the sequence, until this is completed. After removal of the N-terminal Boc group, the resin to which the peptide is bound is carefully washed and dried under vacuum. The peptide is detached from the resin and contemporaneously deprotected by treatment with anhydrous hydrofluoric acid (about 10 ml per g of resin) containing anisole (10% v/v) for 1 h at 0°C. After evaporation of hydrofluoric acid under reduced pressure, the crude peptide is extracted by washing the resin with diluted aqueous acetic acid and the product is isolated by lyophilization. 3. Purification of the crude peptide The crude peptides may be purified by reverse phase preparative HPLC using silanized silica with C18 chain with, for instance, a Waters Prep 500 instrument. Using a 5x30 cm colunm, equilibrated with the suitable aqueous buffer, such as aqueous 0,1% trifluoracetic acid, the crude peptide (about 2 g) is applied on the column and eluted with a gradient containing increasing amounts of acetonitrile. The fractions are checked by analytical HPLC and those containing the product at the desired purity degree (>95%) are collected and lyophilized. Finally, the purified product is transformed in the desired salt by treatment with the desired salt form of an ion-exchange resin. SYNTHESIS OF ARG-LYS-GLU-ARG-ALA-ARG The peptide is synthesized according to the above described general method, starting from the resin containing Boc-N g -tosyl-L-arginine (5 g; substitution: 0.5-0.6 moles per g) and adding the following aminoacids: 1. Boc-L-alanine 2. Boc-N g -tosyl-L-arginine (in DMF) 3. Boc-γ-benzyl-L-glutamic acid 4. Boc-epsilon-benzyloxycarbonyl-L-lysine 5. Boc-N g -tosyl-L-arginine (in DMF) SYNTHESIS OF ARG-LYS-GLU-ARG-D-ALA-ARG The resin substituted with Boc-N g -tosyl-L-arginine (6 g; substitution about 0.5 moles per gram) is sequentially treated with the following aminoacids, according to the above disclosed general protocol: 1. Boc-D-alanine 2. Boc-N g -tosyl-L-arginine (in DMF) 3. Boc-γ-benzyl-L-glutamic acid 4. Boc-epsilon-2- chlorobenzyloxycarbonyl-L-lysine 5. Boc-N g -tosyl-L-arginine (in DMF) SYNTHESIS OF ARG-ALA-ARG-ARG-LYS-GLU The peptide is synthesized according to the above described general method, starting from the resin containing Boc- -benzyl-L-glutamic acid (5 g; substitution: 0.5-0.6 moles per g) and adding the following aminoacids: 1. Boc-epsilon-benzyloxycarbonyl-L-lysine 2. Boc-N g -tosyl-L-arginine (in DMF) 3. Boc-N g -tosyl-L-arginine (in DMF) 4. Boc-L-alanine 5. Boc-N g -tosyl-L-arginine (in DMF) SYNTHESIS OF ARG-D-ALA-ARG-ARG-LYS-GLU The resin substituted with Boc-γ-benzyl-L-glutamic acid (6 g; substitution: about 0.5 moles per g) is treated with the following aminoacid derivatives, according to the above disclosed general method: 1. Boc-epsilon-2-chlorobenzyloxycarbonyl-L-lysine 2. Boc-N g -tosyl-L-arginine (in DMF) 3. Boc-N g -tosyl-L-arginine (in DMF) 4. Boc-D-alanine 5. Boc-N g -tosyl-L-arginine (in DMF) SYNTHESIS OF ARG-ALA-ARG-ARG-LYS-GLU-ARG-ALA-ARG The peptide is synthesized according to the above described general method, starting from the resin containing Boc-N g -tosyl-L-arginine (5 g; substitution: about 0.5 moles per g) and adding the following aminoacids: 1. Boc-L-alanine 2. Boc-N g -tosyl-L-arginine (in DMF) 3. Boc-γ-benzyl-L-glutamic acid 4. Boc-epsilon-2-chlorobenzyloxycarbonyl-L-lysine 5. Boc-N g -tosyl-L-arginine (in DMF) 6. Boc N g -tosyl-L-arginine (in DMF) 7. Boc-L-alanine 8. Boc-N g -tosyl-L-arginine (in DMF) SYNTHESIS OF GLU-LYS-ARG AND RELATED PEPTIDES Boc-N g -Tosyl-L-arginine (substitution approx 0.6 mmole per gram; 20 grams) was treated with the following aminoacid derivative, using the general protocol described previously: 1. Boc-2-chlorobenzyloxycarbonyl 2. Boc-γ-benzyl-L-glutamic acid The previous procedure was repeated using D-glutamic acid instead of L-glutamic acid. Using the same procedures, the following peptides were also prepared: Arg-Ala-Arg-Glu-Lys-Arg Glu-Lys-Arg-Arg-Ala-Arg Glu-Lys-Arg-Arg-Ala-Glu-Lys-Arg EXAMPLE 2 : CHEMICAL CHARACTERISTICS The date hereinbelow reported refer only to a single batch of each peptide and should not be intended in limitative sense. ARG-LYS-GLU-ARG-ALA-ARG Molecular weight : 815.0 Aspect : white powder Aminoacid analysis Aminoacid calcd. found Alanine 1.00 0.97 Lysine 1.00 1.00 Glutamic acid 1.00 1.00 Arginine 3.00 3.05 Peptide content : 80.9% (+/- 0.3%) Peptide purity : 98.62% HPLC : the analysis was carried out using the following methods Eluents : A = NaH2PO4 25mM + NaClO4 60mM, pH 2.9 with H3PO4 B = 60% CH3CN + 40% H2O Gradient : from 100% of a A linear increment of B (1% min) Column : Ultrasphere ODS 5 µm, 4.6mm x 25 cm (Beckman) Flow-rate : 0.9 ml/min. Wavelength: 210 nm Retention time: 21′ ARG-LYS-GLU-ARG-D-ALA-ARG Molecular weight : 815.0 Aspect : white powder Aminoacid analysis Aminoacid calcd. found Alanine 1.00 1.03 Glutamic acid 1.00 1.01 Lysine 1.00 1.00 Arginine 3.00 2.87 Peptide content : 65.9% (+/- 3.0%) Peptide purity : 99.2% HPLC : the analysis was carried out using the following methods Eluents: A = NaH2PO4 25mM + NaClO4 70mM, pH 3.0 with H3PO4 B = 60% CH3CN + 40% H2O Gradient : from 0% to 25% of B in 30 min. Column : Deltapak-C18 15 µm, 3.9mm x 30 cm Flow-rate : 0.7 ml/min. Wavelength: 210 nm Retention time: 22′ ARG-ALA-ARG-ARG-LYS-GLU Molecular weight : 815.0 Aspect : white powder Aminoacid analysis Aminoacid calcd. found Alanine 1.00 1.01 Glutamic acid 1.00 1.00 Lysine 1.00 0.99 Arginine 3.00 3.03 Peptide content : 73.5% (+/- 1.0%) Peptide purity : 99.81% HPLC : the analysis was carried out using the following methods Eluents: A = NaH2PO4 25mM + NaClO4 60mM, pH 2.9 with H3PO4 B = 60% CH3CN + 40% H2O Gradient : from 100% of A linear increment of B (1%/min) Column : Ultrasphere ODS 5 µm, 4.6mm x 25 cm (Beckman) Flow-rate : 0.9 ml/min. Wavelength: 210 nm Retention time: 20′ ARG-ALA-ARG-ARG-LYS-GLU-ARG-ALA-ARG Molecular weight : 1198.5 Aspect : white powder Aminoacid analysis Aminoacid calcd. found Alanine 2.00 2.01 Glutamic acid 1.00 0.99 Lysine 1.00 1.03 Arginine 5.00 4.91 Peptide content : 69.6% (+/- 7.2%) Peptide purity : 99.2% HPLC : the analysis was carried out using the following methods Eluents: A = NaH2PO4 25mM + NaClO4 70mM, pH 3,0 with H3PO4 B = 60% CH3CN + 40% H2O Gradient : from 0% to 30% of B in 25 min. Column : Deltapak-C18 15 µm, 3.9 mm x 30 cm Flow-rate : 0.7 ml/min. Wavelength: 210 nm Retention time: 26′ GLU-LYS-ARG Molecular weight : 431.5 Aspect : white powder Aminoacid analysis Aminoacid calcd. found Glutamic acid 1.00 1.06 Lysine 1.00 0.89 Arginine 1.00 0.94 Peptide content : 71.2% (+/- 3%) Peptide purity : >97% ARG-ALA-ARG-GLU-LYS-ARG Molecular weight : 815 Aminoacid analysis Aminoacid calcd. found Arginine 3.00 3.10 Alanine 1.00 0.90 Glutamic acid 1.00 1.02 Lysine 1.00 0.96 Peptide content : 74.4% Peptide purity : 98.6% RP-TLC : H₂O/CH₃CN/TFA 80/20/0.1 Rf = 0.8 GLU-LYS-ARG-ARG-ALA-ARG Molecular weight : 815 Aminoacid analysis Aminoacid calcd. found Glutamic acid 1.00 1.11 Lysine 1.00 1.00 Arginine 3.00 0.99 Alanine 1.00 2.99 Peptide content : 74.3% Peptide purity : 95% GLU-LYS-ARG-ARG-ALA-ARG-GLU-LYS-ARG Molecular weight : 1228.4 RP-TLC : H₂O/CH₃CN/TFA 80/20/0,1 Rf = 0.8 Aminoacid analysis Aminoacid calcd. found Glutamic acid 2.00 2.00 Alanine 1.00 1.04 Lysine 2.00 1.94 Arginine 4.00 3.97 Peptide content : 83% Peptide purity : >95% EXAMPLE 3 : BIOLOGICAL CHARACTERISTICS Resistance to the in vitro simulated gastric ambient The hexapeptides Arg-Lys-Glu-Arg-Ala-Arg and Arg-Ala-Arg-Arg-Lys-Glu are stable at 37°C for 3 hours in in vitro simulated gastric ambient using the gastric simulated juice USP XXl (HCl + pepsin). In vitro induction of Thy 1.2 antigen in splenocytes from nude mice Spleen cells from congenitally athymic nude mice have been used, after incubation for 18 hours with different peptide concentrations. The induction of the Thy 1.2 marker has been evaluated by direct immunofluorescence, by means of fluorescence microscope. The results, reported in the table, show that the hexapeptides Arg-Lys-Glu-Arg-Ala-Arg and Arg-Ala-Arg-Arg-Lys-Glu are able to induce the appearance of the Thy 1.2 marker, with a bell-shaped dose-response relationship curve, as it is typical for immunostimulating compounds. PEPTIDE CONCENTRATION µg/ml % Thy 1.2+ cells ARG-LYS-GLU-ARG-ALA-ARG ARG-ALA-ARG-ARG-LYS-GLU test 1 test 2 test 1 test 2 0 5 9 5 9 0,0001 7 12 5 10 0,001 10 15 8 18 0,01 18 24 14 22 0,1 28 34 20 30 1 32 39 27 32 10 34 40 28 32 50 31 31 28 25 100 20 24 17 14 RNA synthesis in human T-lymphocytes stimulated in vitro with phythohemagglutinin Human T-lymphocytes incubated in vitro for 24 h, in the presence of 0,5% phytohemagglutinin (PHA) and of different peptide concentrations, have been analyzed for the RNA synthesis by means of 3H-uridine labelling. The results, disclosed in the following tables, show that the tripeptide Glu-Lys-Arg, the hexapeptides Arg-Ala-Arg-Arg-Lys-Glu, Arg-Lys-Glu-Arg-Ala-Arg, Arg-D-Ala-Arg-Arg-Lys-Glu, Arg-Lys-Glu-Arg-D-Ala-Arg and the nonapeptide Arg-Ala-Arg-Arg-Lys-Glu-Arg-Ala-Arg are able to stimulate the RNA synthesis of PHA activated human lymphocytes. PEPTIDE CONCENTRATION mcg/ml 3H-URIDINE INCORPORATION (cpm) ARG-LYS-GLU-ARG-ALA-ARG ARG-ALA-ARG-ARG-LYS-GLU X +/-S.E. Δ% X +/-S.E. Δ% 0 13748 - 13748 - 1806 1806 0.0001 14337 + 4 13490 + 2 1649 1405 0.001 15471 + 13 14395 + 5 1793 1704 0.01 17851 + 30 17285 + 26 2248 1602 0.1 21320 + 55 19939 + 45 2167 2027 1 20403 + 48 18144 + 32 1429 1729 10 20147 + 47 16628 + 21 1338 1371 100 16194 + 18 14397 + 5 702 1044 GLU-LYS-ARG CONCENTRATION µg/ml 3H-URIDINE INCORPORATION (cpm) X (±SE) Δ % 0 2866 (517) - 0.01 3489 (574) + 22 0.1 5149 (545) + 80 1 7883 (311) + 175 10 3609 (1486) + 26 In vitro synthesis of RNA by human lymphocytes activated with anti -T3 monoclonal antibody Human T-lymphocytes activated in vitro with an activator more specific than PHA, i.e. the anti-T3 monoclonal antibody (1.56 ng/ml), were incubated with 1 µg/ml of Glu-Lys-Arg and the RNA synthesis was evaluated by the 3H uridine incorporation. As shown in the Table, also in this case the peptide is able to enhance the RNA synthesis of the already activated cells. PEPTIDE 3H-URIDINE INCORPORATION (cpm) X ±SE Δ % CONTROLS 1155 - 115 GLU-LYS-ARG 3657 + 217 406 In vitro DNA synthesis in human T-lymphocytes stimulated by PHA Human T-lymphocytes incubated in vitro for 72 h in the presence of 0.5% PHA and of different peptide concentrations were analyzed for the DNA synthesis (proliferation) by 3H-thymidine labelling. The results, reported in the following tables, show that the peptides are able to stimulate the DNA synthesis. PEPTIDE CONCENTRATION µg/ml 3H-THYMIDINE INCORPORATION (cpm) ARG-LYS-GLU-ARG-ALA-ARG ARG-ALA-ARG-ARG-LYS-GLU X +/-S.E. Δ% X +/-S.E. Δ% 0 59399 - 59399 - 4346 4346 0.0001 57477 - 3 59758 - 1 5346 4762 0.001 61682 + 4 62751 + 6 4559 4213 0.01 69164 + 16 68755 + 16 1601 2556 0.1 76821 + 29 77401 + 30 3572 3023 1 80920 + 36 78390 + 32 3935 4063 10 74648 + 26 77983 + 31 6772 5975 100 62863 + 6 69780 + 17 7050 6146 GLU-LYS-ARG CONCENTRATION 3H-THYMIDINE INCORPORATION (cpm) X (±SE) Δ % 0 10140 (2205) - 0.01 20648 (4456) + 104 0.1 18660 (6032) + 84 1 22332 (7014) + 120 10 23241 (1209) + 129 In vitro stimulation of ConA-induced proliferation Peripheral blood mononuclear cells (PBMC), obtained from healthy volunteers, were incubated with ConA in order to evaluate the proliferation as labeled thymidine uptake. Stimulation of the in vitro IL-2,BCGF and γ-IFN production by PHA activated cells Human T-lymphocytes have been incubated with PHA in the presence or in the absence of 1 µg of peptides, for 24 h in the case of IL-2, 72 h for BCGF and 36 h for gamma-interferon (γIFN). The supernatants were collected, filtered (0. 2 µm) and assayed for the activity of IL 2 or BCGF by addition at different concentrations of fresh T-lymphocytes or to B-cells coming from long term-cultures. The proliferative activity of said cells, depending on the presence of the corresponding growth-factor, has been evaluated by 3H-thymidine incorporation. The γ-interferon activity in the supernatant has been evaluated by an ELISA kit (AMGEN). The results, reported in the subsequent tables, show a stimulation effect on the lymphokine production by the peptides. Ex-vivo stimulation of mitogen-induced proliferation The stimulation of mitogen-induce proliferation has been investigated by oral or i.p. administration of the peptides to nude athymic mice (body weight 28 g) at the dosage of 10 mcg/mouse, daily for 5 days, 2 or 6 weeks. The animals were sacrificed 24 hours after the last treatment, and the DNA proliferation was determined as labeled thymidine uptake by the spleen cells. The mitogens used were phytohemoagglutinin (PHA), concanavalin A (ConA) and pokeweed mitogen (PWM). As it can be seen from the following tables, the in vivo administration of the peptides stimulates the mitogen-induced proliferation, determined ex-vivo. MITOGEN-INDUCED PROLIFERATION IN NUDE MICE TREATED ORALLY FOR 5 DAYS WITH 10 mcg/mouse OF THE PEPTIDE ARG-LYS-GLU-ARG-ALA-ARG (c.p.m.: mean ± S.E.) MITOGEN % CONTROLS PEPTIDE Δ % PHA 0.00 614 ± 234 630 ± 379 + 3 0.15 1109 ± 511 1515 ± 786 + 37 0.31 3043 ± 519 2965 ± 850 + 45 0.62 1230 ± 104 3047 ± 72 + 145 1.25 1215 ± 116 6034 ± 2962 + 397 2.50 954 ± 182 3738 ± 910 + 292 ConA 0.00 839 ± 657 1093 ± 902 + 30 0.62 903 ± 3 1752 ± 83 + 94 1.25 805 ± 91 2152 ± 297 + 167 2.50 359 ± 143 1657 ± 636 + 362 5.00 197 ± 17 946 ± 323 + 380 10.00 286 ± 50 1071 ± 308 + 274 PWM-INDUCED PROLIFERATION IN NUDE MICE TREATED FOR 5 DAYS WITH 10 mcg/mouse OF ARG-LYS-GLU-ARG-D-ALA-ARG (c.p.m.:mean ± S.E.) % PWM Route of Administr. CONTROLS PEPTIDE Δ % 0.00 oral 914 ± 336 888 ± 97 - 3 0.15 " 867 ± 291 3914 ± 1055 + 351 0.31 " 2855 ± 1279 7076 ± 777 + 148 0.62 " 1246 ± 549 2821 ± 1476 + 126 1.25 " 681 ± 168 657 ± 170 - 4 2.50 " 727 ± 150 634 ± 30 - 13 0.00 i.p. 1728 ± 501 2103 ± 351 + 22 0.15 " 5352 ± 2925 9028 ± 1641 + 69 0.31 " 3882 ± 1654 7027 ± 1059 + 81 0.62 " 2501 ± 1353 5999 ± 3205 + 140 1.25 " 2334 ± 920 4187 ± 842 + 79 2.50 " 2609 ± 1561 4201 ± 2139 + 61 MITOGEN-INDUCED PROLIFERATION IN NUDE MICE TREATED FOR 2 WEEKS WITH 10 mcg/mouse OF THE PEPTIDE BY ORAL ROUTE (c.p.m.: mean ± S.E.) MITOGEN % CONTROLS GLU-LYS-ARG Δ % PHA 0.00 4140 ± 196 4672 ± 131 + 13 0.50 4201 ± 506 6876 ± 963 + 63 0.75 4098 ± 301 7740 ± 630 + 89 1.00 4607 ± 533 19842 ± 594 + 383 2.00 4470 ± 343 35657 ± 619 + 698 ConA 0.00 4269 ± 587 3528 ± 516 - 18 0.50 4272 ± 77 113536 ±17906 +2558 0.75 3896 ± 384 73952 ± 4889 +1798 1.00 4194 ± 709 6805 ± 389 + 62 2.00 1517 ± 362 762 ± 240 - 50 PWM 0.00 1363 ± 162 2319 ± 220 + 70 0.50 2074 ± 206 22126 ± 2811 + 967 0.75 1990 ± 28 21448 ± 717 + 978 1.00 2351 ± 873 21919 ± 2506 + 832 2.00 1602 ± 109 12816 ± 839 + 700 MITOGEN-INDUCED PROLIFERATION IN NUDE MICE TREATED FOR 6 WEEKS WITH 10 mcg/mouse OF THE PEPTIDE BY ORAL ROUTE (c.p.m.: mean ± S.E.) MITOGEN % CONTROLS GLU-LYS-ARG Δ % ConA 0.00 1001 ± 587 2671 ± 331 + 167 0.25 3568 ± 71 4825 ± 877 + 35 0.50 2670 ± 39 5311 ± 1030 + 99 1.00 3103 ± 123 7361 ± 404 + 137 2.00 2128 ± 106 3141 ± 101 + 48 4.00 853 ± 16 959 ± 221 + 12 PWM 0.00 1228 ± 175 3779 ± 1142 + 208 0.125 779 ± 50 2264 ± 198 + 191 0.25 1106 ± 167 2124 ± 211 + 92 0.50 2322 ± 299 2646 ± 141 + 14 1.00 1146 ± 476 2616 ± 64 + 128 2.00 898 ± 323 2607 ± 584 + 190 MITOGEN-INDUCED PROLIFERATION IN NUDE MICE TREATED I.P. FOR 6 WEEKS WITH 10 mcg/mouse OF THE PEPTIDE (c.p.m.: mean ± S.E.) MITOGEN % CONTROLS GLU-LYS-ARG Δ % ConA 0.00 2015 ± 159 2583 ± 491 + 28 0.25 2084 ± 101 6486 ± 388 + 211 0.50 2313 ± 157 10099 ± 584 + 337 1.00 3289 ± 133 17192 ± 169 + 423 2.00 2498 ± 647 10850 ± 1459 + 334 4.00 1525 ± 107 2472 ± 901 + 62 PWM 0.00 1936 ± 150 2856 ± 113 + 48 0.125 2464 ± 297 3437 ± 914 + 39 0.25 2991 ± 95 3955 ± 193 + 32 0.50 2434 ± 540 3503 ± 502 + 44 1.00 3177 ± 292 3246 ± 860 + 3 2.00 2509 ± 359 2453 ± 467 - 2 EXAMPLE 4 : ACUTE TOXICITY The peptides of the invention had a LD₅₀ higher than 500 mg/kg i.p. in the mouse.

Claims: Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE Peptides of formula I A - x - Lys - y - B I in which: A is H, a tripeptide of formula Arg-Ala-Arg or an hexapeptide of formula Glu-Lys-Arg-Arg-Ala-Arg x and y, different one from the other, are an arginine (Arg) or a glutamic acid (Glu) residue; B is OH or a tripeptide Arg-Ala-Arg with the proviso that when A is hydrogen and x is Arg, B is different from OH and pharmaceutically acceptable salts thereof. Peptides of formula I wherein the aminoacids are of the D-, L- or DL series. Acetate, trifluoroacetate, sulfate, hydrochloride salts of peptides of formula I. A peptide according to claim 1 or 2 selected in the group consisting of Arg-Lys-Glu-Arg-Ala-Arg, Arg-Lys-Glu-Arg-D-Ala-Arg, Arg-Ala-Arg-Arg-Lys-Glu, Arg-D-Ala-Arg-Arg-Lys-Glu, Arg-Ala-Arg-Arg-Lys-Glu-Arg-Ala-Arg, Glu-Lys-Arg, Arg-Ala-Arg-Glu-Lys-Arg, Glu-Lys-Arg-Arg-Ala-Arg, Glu-Lys-Arg-Arg-Ala-Arg-Glu-Lys-Arg. A pharmaceutical composition having immunostimulating activity comprising as the active principle a peptide of claims 1-4 in admixture with an acceptable carrier. Use of the peptides of claims 1-4 for the preparation of medicaments having immunostimulating activity for the treatment of primary and secondary immunodeficiencies. A process for the preparation of peptides of formula I A - x - Lys - y - B I in which: A is H, a tripeptide of formula Arg-Ala-Arg or an hexapeptide of formula Glu-Lys-Arg-Arg-Ala-Arg x and y, different one from the other, are an arginine (Arg) or a glutamic acid (Glu) residue; B is OH or a tripeptide Arg-Ala-Arg with the proviso that when A is hydrogen and x is Arg, B is different from OH comprising the steps of: a) binding the Boc-protected carboxyterminal aminoacid to a suitable resin; b) reacting the other Boc-protected aminoacids with the resin-bound carboxyterminal aminoacid in the desired sequence; c) removing the protecting groups and releasing the so obtained peptides from the resin. Claim for the following Contracting States: ES, GR A process for the preparation of peptides of formula I A - x - Lys - y - B I in which: A is H, a tripeptide of formula Arg-Ala-Arg or an hexapeptide of formula Glu-Lys-Arg-Arg-Ala-Arg x and y, different one from the other, are an arginine (Arg) or a glutamic acid (Glu) residue; B is OH or a tripeptide Arg-Ala-Arg with the proviso that when A is hydrogen and x is Arg, B is different from OH comprising the steps of: a) binding the Boc-protected carboxyterminal aminoacid to a suitable resin; b) reacting the other Boc-protected aminoacids with the resin-bound carboxyterminal aminoacid in the desired sequence; c) removing the protecting groups and releasing the so obtained peptides from the resin.

Inventors: BRUNETTI, BRUNETTO, PRADA, MARCO
Applicants: ELLEM INDUSTRIA FARMACEUTICA S.P.A.
Application year: 1989
Main classification: C07K7
IPC codes: C07K14, C07K1, C07K5, A61K38, C07K7, A61P37